Aller au contenu principal Activer le contraste adaptéDésactiver le contraste adapté
Fermer
CAC 40
7 652,69
+0,34%
  2. Aide
  2. Aide
Plus de 40000 produits accessibles à 0€ de frais de courtage
Découvrir Boursomarkets
CAC 40
7 652,69
+0,34%
Indices
 
Chiffres-clés
 
+ fortes hausses et baisses SBF 120

All of Transgene’s preclinical and clinical assets progressed in line with expectations in Q1 2022
information fournie par Boursorama CP 10/05/2022 à 17:45

-­ TG4050 – New positive preliminary Phase I results presented at AACR 2022; additional clinical data to be presented at ASCO 2022
­
- BT-001 – Preclinical data presented at AACR 2022. Phase I clinical update to be released in Q2 2022

­- Dr. Alessandro Riva proposed as new independent Director and non-executive Chairman of the Board, separating the roles of Chairman and Chief Executive Officer

­- €46.8 million in cash and cash equivalents as of March 31, 2022 – Confirmed financial visibility until the end of 2023

.../...

Valeurs associées

TRANSGENE
0,6040 EUR Euronext Paris -0,33%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

Cette liste ne contient aucune valeur.

Pages les plus populaires

L'offre BoursoBank